IONS Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. (IONS) is expected to report earnings on October 28, 2026, before the market open. The consensus earnings estimate is a loss of $1.21 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +3.9% since its last earnings release on July 29, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Ionis Pharmaceuticals, Inc.
For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology.
Sector
Healthcare
Industry
Drug Manufacturers/Other